Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

被引:182
作者
Neumann, AU
Lam, NP
Dahari, H
Davidian, M
Wiley, TE
Mika, BP
Perelson, AS
Layden, TJ
机构
[1] Univ Illinois, Sect Digest & Liver Dis, Dept Med, Chicago, IL 60612 USA
[2] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel
[3] Santa Fe Inst, Santa Fe, NM 87501 USA
[4] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA
[5] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM USA
关键词
D O I
10.1086/315661
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Many studies have shown that patients infected with hepatitis C virus (HCV) of genotype 2 have better response to interferon (IFN)-alpha treatment than genotype 1 patients; however, the mechanisms responsible for this difference are not understood. In this study, viral dynamics during high-dose IFN induction treatment were compared between the genotypes, Patients in each group received 10 MU of IFN-alpha 2b for 14 days, and HCV RNA levels were frequently determined. Nonlinear fitting, both individually for each patient and using a mixed-effects approach, of the viral kinetic data to a mathematical model of the IFN effect on HCV infection was performed, The antiviral effectiveness of IFN in blocking virus production, the free virion clearance rate, and the HCV-infected cell death rate were all significantly higher for genotype 2 patients than for genotype 1 patients. Thus, the better response rate of patients infected with HCV genotype 2 is multifactorial, This is the first finding of a difference in viral dynamics between subtypes of the same virus and demonstrates the importance of subtype-specific virus-host-drug interactions.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 39 条
[1]   Epidemiology of hepatitis C [J].
Alter, MJ .
HEPATOLOGY, 1997, 26 (03) :S62-S65
[2]  
[Anonymous], 1999, J Hepatol, V30, P956
[3]  
[Anonymous], 1997, HEPATOLOGY, V26, pS2
[4]  
Bekkering FC, 1997, HEPATOLOGY, V26, P1691
[5]   Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease [J].
Brambilla, S ;
Bellati, G ;
Asti, M ;
Lisa, A ;
Candusso, ME ;
D'Amico, M ;
Grassi, G ;
Giacca, M ;
Franchini, A ;
Bruno, S ;
Ideo, G ;
Mondelli, MU ;
Silini, EM .
HEPATOLOGY, 1998, 27 (06) :1678-1686
[6]  
*DAT PROD DIV, 1997, MATHS S PLUS 4 GUID
[7]  
Davidian M., 1995, NONLINEAR MODELS REP
[8]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[9]  
DAVIS GL, 1998, HEPATOLOGY S4 2, V28, pA99
[10]   Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection [J].
Enomoto, N ;
Sakuma, I ;
Asahina, Y ;
Kurosaki, M ;
Murakami, T ;
Yamamoto, C ;
Ogura, Y ;
Izumi, N ;
Marumo, F ;
Sato, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) :77-81